Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-7,100
Closed -$1K 3990
2023
Q1
$1K Sell
7,100
-29,200
-80% -$269K ﹤0.01% 3497
2022
Q4
$11K Buy
36,300
+21,800
+150% +$385K ﹤0.01% 2645
2022
Q3
$2K Sell
14,500
-20,600
-59% -$893K ﹤0.01% 4256
2022
Q2
$58K Sell
35,100
-54,800
-61% -$2.84M ﹤0.01% 1840
2022
Q1
$298K Buy
89,900
+15,600
+21% +$1.39M 0.02% 946
2021
Q4
$437K Buy
74,300
+56,300
+313% +$9.67M 0.02% 822
2021
Q3
$720K Sell
18,000
-400
-2% -$88.2K 0.03% 604
2021
Q2
$749K Buy
18,400
+1,300
+8% +$238K 0.03% 576
2021
Q1
$759K Buy
17,100
+6,400
+60% +$1.28M 0.04% 549
2020
Q4
$333K Sell
10,700
-7,900
-42% -$840K 0.02% 819
2020
Q3
$483K Sell
18,600
-18,100
-49% -$2.2M 0.03% 547
2020
Q2
$447K Buy
36,700
+16,900
+85% +$646K 0.03% 530
2020
Q1
$31K Buy
+19,800
New +$168K ﹤0.01% 2044
2017
Q2
Sell
-1,440
Closed -$1K 6837
2017
Q1
$1K Sell
1,440
-4,125
-74% -$113K ﹤0.01% 5924
2016
Q4
$6K Buy
5,565
+1,050
+23% +$30.6K ﹤0.01% 4772
2016
Q3
$6K Buy
4,515
+1,005
+29% +$130K ﹤0.01% 4777
2016
Q2
$137K Buy
3,510
+1,185
+51% +$136K 0.01% 1420
2016
Q1
$26K Sell
2,325
-3,830
-62% -$411K ﹤0.01% 3010
2015
Q4
$107K Buy
+6,155
New +$947K 0.01% 1706

Other funds holding NVAX

Cutler Group's NVAX Position: Q1 2024 in Review

Cutler Group reduced its Novavax (NVAX) stake by 55% in Q1 2024, selling an estimated $2.78K and leaving 500 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1878.

Cutler Group first reported a position in NVAX in Q4 2015 and has held it in 28 quarters since. The position peaked at $3.3M in Q4 2021. 201 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

  • Cutler Group held 500 shares of Novavax worth $2K as of Q1 2024.
  • Cutler Group sold 600 Novavax shares in Q1 2024, an estimated $2.78K.
  • Novavax made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1878 holding.
  • Cutler Group first reported a position in Novavax in Q4 2015 and has held it in 28 quarters since.
  • Cutler Group's Novavax position peaked at $3.3M in Q4 2021.
  • 201 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.